Mechanisms of Inhibition of Human Monoclonal Antibodies in Immune Thrombotic Thrombocytopenic Purpura
Blood · 06.04.2023
DOI: 10.1182/blood.2022019252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood, online erschienen am 06.04.2023. Verfasst von Konstantine Halkidis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City…. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Thrombosis, Purpura, Thrombocytopenic, Idiopathic. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Antibody binding to a plasma metalloprotease ADAMTS13 is necessary for the development of immune thrombotic thrombocytopenic purpura (iTTP). Inhibition of ADAMTS13-mediated VWF cleavage by such antibodies clearly plays a role in the pathophysiology of the disease, though the mechanisms by which they inhibit ADAMTS13 enzymatic function are not fully understood. At least some immunoglobulin G-type antibodies appear to affect the conformational accessibility of ADAMTS13 domains involved in both substrate recognition and inhibitory antibody binding. We utilized single chain fragments of the variable region (scFv's) previously identified via phage display from patients with iTTP to explore the mechanisms of action of inhibitory human monoclonal antibodies. Using recombinant full-length ADAMTS13, truncated ADAMTS13 variants, and native ADAMTS13 in normal human plasma, we found that, regardless of the conditions tested, all three inhibitory monoclonal antibodies affect enzyme turnover rate much more than substrate recognition of von Willebrand factor (VWF). Hydrogen-deuterium exchange plus mass spectrometry (HX-MS) experiments with each of these inhibitory antibodies demonstrated that residues in the active site of the catalytic domain of ADAMTS13 are differentially exposed to solvent in the presence and absence of monoclonal antibody binding. These results support the hypothesis that inhibition of ADAMTS13 in iTTP may not necessarily occur because the antibodies directly prevent VWF binding, but instead rely on allosteric effects that impair VWF cleavage, likely by affecting the conformation of the catalytic center in the protease domain of ADAMTS13. Our findings provide novel insight into the mechanism of autoantibody-mediated inhibition of ADAMTS13 and pathogenesis of iTTP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Hematologic Malignancies and Cellular Therapeutics, Department of Internal Medicine, The University of Kansas Medical Center, Kansas City, KS.
- Department of Pathology and Laboratory Medicine, The University of Kansas Medical Center, Kansas City, KS.
- Department of Biochemistry and Molecular Biophysics, University of Pennsylvania, Philadelphia, PA.
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA.
- Institute of Reproductive Medicine and Developmental Sciences, The University of Kansas Medical Center, Kansas City, KS.
ORCID-Profile: Konstantine Halkidis, Szumam Liu, X Long Zheng
Förderung
- NHLBI NIH HHS
Zitieren
APA
Halkidis, K., Meng, C., Liu, S., Mayne, L., Siegel, D. L., & Zheng, X. L. (2023). Mechanisms of Inhibition of Human Monoclonal Antibodies in Immune Thrombotic Thrombocytopenic Purpura. Blood. https://doi.org/10.1182/blood.2022019252
Vancouver
Halkidis K, Meng C, Liu S, Mayne L, Siegel DL, Zheng XL. Mechanisms of Inhibition of Human Monoclonal Antibodies in Immune Thrombotic Thrombocytopenic Purpura. Blood. 2023. doi:10.1182/blood.2022019252
BibTeX
@article{Halkidis2023,
author = {Halkidis, Konstantine and Meng, Chan and Liu, Szumam and Mayne, Leland and Siegel, Don L and Zheng, X Long},
title = {Mechanisms of Inhibition of Human Monoclonal Antibodies in Immune Thrombotic Thrombocytopenic Purpura},
journal = {Blood},
year = {2023},
doi = {10.1182/blood.2022019252}
}
EUVIMED